Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study

TRAK-ER is a multicenter study of 3-monthly tumor-informed ctDNA surveillance (Labcorp) during adjuvant endocrine therapy in high-risk ER-positive, HER2-negative early breast cancer. Panel design failed in 16.1% (178 of 1,106), and 912 patients started surveillance. The patient-level detection rate was 12.0% (109 of 912). Among patients whose first positive test was the initial draw, 65.9% (29 of 44) already had radiologic recurrence, compared with 26.6% (17 of 64) when the first positive test came later.

Annals of OncologyPubMed 42946309DOI 10.1016/j.annonc.2026.10.1292